&nbsp;

Oct 2023

Drug

regorafenib

Other Name(s): Stivarga®

Quick Link(s):

Nov 2023

Drug

romidepsin

Other Name(s): Istodax®

Quick Link(s):

Mar 2023

Drug

ramucirumab

Other Name(s): Cyramza®

Quick Link(s):

Mar 2023

Regimen

REGO

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Drugs Used:

regorafenib (Unfunded)

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

REGO

Cancer Type:

Gastrointestinal,

Gastrointestinal Stromal Tumours,

Sarcoma,

GIST

Intent: Palliative

Funding:

Exceptional Access Program

Drugs Used:

regorafenib

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

RAMU

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Drugs Used:

ramucirumab (Unfunded)

Quick Link(s):

Regimen Monograph

Mar 2023

Regimen

IDEL+RITU; IDEL(MNT)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

idelalisib - For the treatment of relapsed chronic lymphocytic leukemia, in combination with rituximab, according to specific clinical criteria

New Drug Funding Program

Rituximab (Biosimilar IV) - In Combination with Idelalisib - Relapsed Chronic Lymphocytic Leukemia

Drugs Used:

idelalisib,

riTUXimab

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

REGO

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

Exceptional Access Program

regorafenib - For the treatment of unresectable, advanced hepatocellular carcinoma (HCC) according to clinical criteria

Drugs Used:

regorafenib

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

IRINRALT

Cancer Type:

Gastrointestinal,

Colorectal,

Esophagus,

Gastric / Stomach,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer

New Drug Funding Program

Raltitrexed - Metastatic Esophageal, Gastroesophageal Junction, or Gastric Cancer

Drugs Used:

irinotecan,

raltitrexed

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

INOT

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Palliative

Funding:

New Drug Funding Program

Inotuzumab Ozogamicin (Outpatient) - Relapsed or Refractory Acute Lymphoblastic Leukemia

Drugs Used:

inotuzumab ozogamicin

Quick Link(s):

Regimen Monograph

Jul 2023

Drug

inotuzumab ozogamicin

Other Name(s): Besponsa®

Quick Link(s):